Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 19.96M | 19.63M | 14.92M | 9.83M | 26.54M | 11.24M |
Gross Profit | 19.04M | 16.28M | -59.21M | 3.74M | 26.46M | 11.24M |
EBITDA | -49.68M | -58.83M | -85.89M | -51.99M | -40.11M | -27.93M |
Net Income | -50.77M | -60.48M | -86.88M | -61.23M | -40.78M | -28.35M |
Balance Sheet | ||||||
Total Assets | 15.95M | 30.46M | 89.55M | 72.15M | 35.45M | 58.46M |
Cash, Cash Equivalents and Short-Term Investments | 7.74M | 17.91M | 77.61M | 52.00M | 28.55M | 51.79M |
Total Debt | 2.33M | 2.48M | 3.12M | 40.16M | 2.63M | 3.44M |
Total Liabilities | 52.62M | 58.37M | 63.02M | 101.28M | 9.43M | 8.31M |
Stockholders Equity | -36.66M | -27.91M | 26.53M | -49.26M | 11.63M | 35.76M |
Cash Flow | ||||||
Free Cash Flow | -47.66M | -60.04M | -82.31M | -12.23M | -39.20M | -27.45M |
Operating Cash Flow | -47.56M | -59.92M | -81.18M | -7.57M | -37.33M | -27.01M |
Investing Cash Flow | 418.00K | -123.00K | 72.41M | -32.56M | -1.87M | -440.00K |
Financing Cash Flow | -1.63M | 344.00K | 62.18M | 35.77M | 15.96M | 72.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$15.71B | 5.67 | -7.43% | 4.09% | 11.60% | -21.06% | |
56 Neutral | $8.67M | 4.67 | -41.13% | ― | ― | ― | |
49 Neutral | $9.17M | ― | -451.34% | ― | ― | -57.84% | |
43 Neutral | $16.84M | ― | -362.79% | ― | 32.45% | 39.31% | |
39 Underperform | $11.32M | ― | -285.79% | ― | ― | 23.65% | |
34 Underperform | $8.37M | ― | -126.03% | ― | -100.00% | -27.44% |
On June 22, 2025, Carisma Therapeutics announced a merger agreement with OrthoCellix, a subsidiary of Ocugen, to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The merger will result in OrthoCellix owning approximately 90% of the combined entity, with plans to initiate a Phase 3 clinical trial for its NeoCart® technology by the end of 2025, potentially impacting the market for cartilage repair solutions.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.